As one of the most common human viruses in the world, the Epstein-Barr virus (EBV) is also the most prevalent cause of infectious mononucleosis, also known as “the kissing disease.” The virus is a member of the herpes virus family, as indicated
by the Centers for Disease Control and Prevention (CDC), a family of viruses that is also linked to cancer
through human papillomavirus. Recently, a team of researchers in the United Kingdom has discovered the pathway through which the EBV can lead to certain blood cancers.
According to the CDC, most individuals will be infected with EBV at some point in their lifetime. The virus spreads primarily through saliva shared by kissing, shared food and drinks, shared eating utensils, and among children through drool on toys or surfaces. While many individuals with an EBV infection do not exhibit symptoms—particularly children—common signs include fatigue, fever, an inflamed throat, rash, and swelling in the lymph nodes, spleen, or liver. Symptoms usually pass within two to four weeks, though some cases can be more prolonged, with fatigue lasting up to several months.
Infectious mononucleosis, or “mono," can be caused by other viruses, but is most often brought on by EBV. With no vaccine available to prevent these illnesses, the best line of defense is prevention by avoiding kissing and sharing food or drinks with anyone who may have infectious mononucleosis.
In 1964, The Lancet
published the first study
showing that a virus can cause cancer. That virus came to be known as Epstein-Barr virus, named after the researchers who made the important finding. Included among the many EBV-related conditions
are cancers such as Burkitt’s lymphoma, Hodgkin’s disease and non-Hodgkin’s lymphoma, and Nasopharyngeal carcinoma. Scientists have been researching the link between the virus and these cancers since the link between them was first discovered more than 50 years ago. Now, in the new study led by University of Sussex professor Michelle West, PhD, researchers have found how the virus works on a genetic level to drive the development of cancer. Their paper
was recently published in the open-access journal eLIFE
In their findings, the authors describe their investigation into how EBV controls the genes MYC
, essentially switching on the MYC
gene to trigger development of lymphoma and switching off the BCL2L11
gene that causes cell death and stops lymphoma. Studying human B cells infected with EBV, the team observed how the virus works to reconfigure the DNA loops between MYC
and their enhancers, which activate and increase the rate of transcription of a gene. They discovered that EBV works by essentially hijacking these enhancers and taking over the control centers that contact and regulate MYC
. The virus increases contact between a set of enhancers and the MYC
gene to turn on that gene. At the same time, the researchers observed new enhancers of the BCL211
gene and found that the virus effectively blocks contact between them. They also found that with an available drug they can be used to reverse silencing of the BCL211
gene, which could offer an effective way to prevent EBV-related cancer.